Spectrum v15 reduces 5 weeks of manual work to 5 minutes, provides study sponsors and CROs a fast way to navigate the path to ...

In this video interview, Rob Jones, product manager, TMF practice area, Pharmalex, highlights recent ICH guidelines and how risk should be an area of focus as trial designs continue to get more ...

Cobenfy (xanomeline and trospium chloride) as an adjunctive treatment to atypical antipsychotics demonstrated a 2.0-point ...

Novel CAR design selectively targets malignant cells for patients with relapsed/refractory CD5-positive hematological diseasesHOUSTON, April 22, ...

Chico, Vice President and Global Head of Oncology Therapeutic Expertise at Fortrea, shares how scientific advances, AI tools ...

CURE provides access to the cancer news, latest oncology research & expert insights that serve as a guide to every stage of ...

BMS has reported topline outcomes from the ARISE trial of Cobenfy as an adjunctive treatment to atypical antipsychotics for ...

Oncology Clinical Trial Market Roche is actively conducting pivotal trials for novel therapies targeting advanced breast cancer, aiming to ...

Following a recent Type D meeting with the FDA, a phase 3 clinical trial design for darovasertib in primary uveal melanoma ...

Metro International Biotech, LLC (MetroBiotech), an EdenRoc Sciences company that is developing more effective treatments of ...

DT-168 is a GeneTAC® small molecule, formulated as an eye drop, that is designed to selectively target the CTG repeat expansion in the TCF4 gene and reduce the expression of the mutant gene product ...